MannKind Corp.

$4.21 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About MannKind Corp.

MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company's product candidate is Afrezza (insulin human) Inhalation Powder, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its technosphere formulation technology. The technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics.

Stock Analysis

last close $4.32
1-mo return 19%
3-mo return 27.1%
avg daily vol. 5.01M
52-week high 6.25
52-week low 1.02
market cap. $1.0B
forward pe -
annual div. -
roe -
ltg forecast 35.6%
dividend yield -
annual rev. $65M
inst own. 30.7%

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist